Tag: Stock pick

  • Rates are rising. Are Australia’s biggest bank shares still worth buying?

    A man in a suit smiles at the yellow piggy bank he holds in his hand.

    The last time Australia faced back-to-back interest rate rises, most investors were hoping the worst was behind them.

    Not anymore.

    The Reserve Bank of Australia has now raised the cash rate to 4.1%, following a hike in February, and all four major banks had tipped this move as a near certainty heading into today’s decision. That is two increases in a matter of months, reversing much of the easing cycle that played out through 2025. The catalyst is well-known: persistent inflation, a tight labour market, and an oil shock from the Middle East conflict that has complicated the RBA’s path back to target.

    For shareholders in Commonwealth Bank of Australia (ASX: CBA), the question is what any of this actually means for one of the ASX’s most closely watched businesses.

    The rate rise paradox

    Higher interest rates are, in theory, good for banks. When the cash rate rises, lenders can reprice their loan books faster than their deposit costs, widening the net interest margin (NIM) — the spread between what a bank charges borrowers and what it pays savers. Commonwealth Bank’s NIM is already among the strongest of the major banks.

    But there is a catch. That same rate rise squeezes the customers Commonwealth Bank relies on.

    With the cash rate now at 4.1%, and potentially heading higher again in May if inflation data stays sticky, mortgage holders are absorbing real pressure. Each 25 basis point rise adds roughly $90 per month to repayments on a $600,000 loan. Two rises in 2026 alone adds $180 per month for millions of Australian households — many of whom bank with the big four.

    The risk is not just sentiment; it is also credit quality. Higher rates for longer raise the probability of loan arrears climbing and some borrowers falling into difficulty. The RBA’s own forecasts project unemployment will rise gradually toward 4.6% by mid-2028 as tighter policy slows growth. That headwind does not hit immediately, but it builds.

    What does the current valuation actually tell you?

    Commonwealth Bank shares are currently trading around $176, which puts the price-to-earnings ratio at roughly 28 times. That is the highest valuation of the big four banks, and well above the long-run average for Australian banking stocks as a sector.

    To put that in context: the trailing dividend yield sits at close to 2.9%, fully franked. The most recent interim dividend was $2.35 per share, paid in late March. For income-focused investors, the franking credits add meaningful value on a grossed-up basis. However, compared to where Commonwealth bank has historically yielded — and compared to peers like National Australia Bank Ltd (ASX: NAB) and Westpac Banking Corporation (ASX: WBC), which trade at lower multiples and higher yields — the income argument for buying Commonwealth Bank at current prices is relatively thin.

    The premium has always been there, and it has always been justified to a degree. Commonwealth Bank’s H1 FY2026 cash net profit after tax came in at $5.45 billion, up 6% on the prior period. Return on equity remains among the highest in the sector. The brand, the scale, and the technology investment program are genuine competitive advantages that peers have not been able to replicate.

    Yet, a premium valuation priced for near-perfection leaves limited room for error. If net interest margins normalise as competition for deposits intensifies, or if loan impairments tick up in a higher-for-longer rate environment, that 28 times multiple becomes harder to defend.

    The Foolish takeaway

    Commonwealth Bank is not a bad business. It is arguably one of the best-run banks in the world, and it has consistently rewarded long-term shareholders who held through noise and uncertainty.

    The honest question in 2026 is whether the current price already reflects all of that quality, and then some. At 28 times earnings with a sub-3% yield, investors are paying a significant premium over peers for a franchise that, while exceptional, faces the same credit cycle headwinds as every other lender. That does not make the shares uninvestable. But for investors weighing up where to put new capital in a rising rate environment, the price being asked for Commonwealth Bank deserves careful thought.

    The post Rates are rising. Are Australia’s biggest bank shares still worth buying? appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Commonwealth Bank of Australia right now?

    Before you buy Commonwealth Bank of Australia shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Commonwealth Bank of Australia wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 20 Feb 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Leigh Gant has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • 2 top ASX shares I’d buy right now in this March madness

    Person pointing at an increasing blue graph which represents a rising share price.

    The sell-off we’ve seen in March has been hefty and adds to the declines that many ASX growth shares have seen this year.

    I don’t know how long energy prices will stay elevated, but I don’t think it will be forever.

    Lower share prices give brave investors the chance to buy businesses at a lower valuation that would have been unthinkable last year. It’s possible shares could go even lower, but after all the pain, I think the following ASX shares are great contenders to buy for a possible future recovery.

    Temple & Webster Group Ltd (ASX: TPW)

    Temple & Webster is one of Australia’s leading retailers, in my view. It sells hundreds of thousands of homewares, furniture, and home improvement products.

    As the chart below shows, the company has fallen 54% since the start of the year and 27% in the past month.

    It’s normal for retailers to face elevated volatility because of worries about what could happen to consumer spending. Higher energy prices and the flow-on to overall inflation could be a negative.

    But in the long term, I think this valuation below $7 will be a great time to buy.

    It’s still growing strongly. The FY26 half-year financials showed how revenue rose by 19.8% to $375.9 million, while revenue in the second half of FY26 (to 9 February 2026) showed 20% revenue growth year over year.

    The company is gaining market share, and this should have long-term benefits thanks to operating leverage, but it’s sacrificing profitability in the short term to do so.

    Technology is helping the ASX share reduce costs, and growing scale is helping it reduce fixed costs as a percentage of revenue. Temple & Webster is forecasting its FY26 operating profit (EBITDA) margin to be between 3% to 5% in FY26, with expectations that the EBTIDA margin could climb to at least 15% in the long term.

    I’m bullish about its growth as more people adopt online shopping for homewares and furniture. The online penetration of this category is currently around 20% in Australia – it has reached 29% in the UK and 35% in the US.

    Home improvement is also an exciting segment because it could undergo significant online adoption. The ASX share’s home improvement revenue grew 47% in HY26 to $30 million.

    In three years, I think this company will be much bigger and more profitable.

    REA Group Ltd (ASX: REA)

    REA Group has been one of the ASX’s best growth shares of the past 20 years, but the share price hasn’t been the strong performer it used to be. As the chart below shows, it’s down 31% in the past six months and 14% in 2026 to date.

    It’s the owner of realestate.com.au, Australia’s leading portal for finding residential property. The business also has a number of other property businesses/investments such as realcommercial.com.au, flatmates.com.au, PropTrack, Mortgage Choice, REA India, and Move Inc (a US business).

    Higher interest rates may be a headwind for property prices, but they could be a tailwind for REA Group earnings if they lead to a higher level of property listings and more revenue for the ASX tech share.

    I believe the ASX share’s strong market position – it receives significantly more property buyer and seller attention than the competition – will allow it to continue delivering underlying earnings growth in the next few years, making the current valuation look cheap.

    At the time of writing, the REA Group share price is valued at under 30x FY27’s estimated earnings, according to CommSec.

    The post 2 top ASX shares I’d buy right now in this March madness appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now…

    * Returns as of 20 Feb 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Tristan Harrison has positions in Temple & Webster Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Temple & Webster Group. The Motley Fool Australia has recommended Temple & Webster Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • 2 ASX mining stocks that could rise 60% to 100%+

    A female miner wearing a high vis vest and hard hard smiles and holds a clipboard while inspecting a mine site with a colleague.

    Are you looking for ASX mining stocks to buy outside the status quo of BHP Group Ltd (ASX: BHP) and Rio Tinto Ltd (ASX: RIO)?

    If you are, then it could be worth considering the two in this article.

    That’s because the team at Morgans has just named them as buys and is predicting major upside over the next 12 months.

    Here’s what the broker is recommending to clients in the mining sector:

    29Metals Ltd (ASX: 29M)

    This copper miner has caught the eye of Morgans following its recent equity raising. The broker believes this leaves 29Metals well-positioned to execute on its growth plans.

    This morning, the broker has initiated coverage on the ASX mining stock with a buy rating and 54 cents price target. Based on its current share price of 34 cents, this implies potential upside of almost 60% for investors. It said:

    We initiate coverage on 29Metals (29M) with a 12-month target price of A$0.54ps and a BUY recommendation. We expect the Xantho Extended restart and Gossan Valley development at Golden Grove to restore grades and operating flexibility, while a potential Capricorn Copper restart provides medium-term production growth. Following its recent equity raise, 29M is better positioned to execute its plans, with upside potential supported by a constructive long-term copper outlook.

    Meeka Metals Ltd (ASX: MEK)

    Another ASX mining stock that Morgans is positive on is gold miner Meeka Metals.

    It highlights that the company is planning to expand its production capability with a modest capital investment.

    While it suspects there could be some short-term production challenges, it believes things will pick up from the fourth quarter.

    As a result, it has retained its buy rating and 39 cents price target on its shares. Based on its current share price of 15.7 cents, this suggests that its shares could more than double in value. Morgans commented:

    MEK announced an expansion to 800ktpa (equivalent ounce basis) via ore sorting, requiring modest capex of A$6m with commissioning scheduled for Q1FY27. Ore sorting effectively near doubles Andy Well underground head grade, lifting our annual production forecasts by an average of 7% from FY27 onwards.

    Open Pit throughput has tracked below DFS forecasts due to moisture-driven variability in open pit ore, an issue expected to resolve with underground stope commencement in 4QFY26. We revise our FY26 production forecast to 37.6koz Au (from 40.2koz), this is below the DFS guidance. We maintain our BUY rating and A$0.39ps price target, acknowledging near-term production softness may weigh on the 3Q result ahead of an anticipated step-change in output in 4Q.

    The post 2 ASX mining stocks that could rise 60% to 100%+ appeared first on The Motley Fool Australia.

    Should you invest $1,000 in 29Metals Limited right now?

    Before you buy 29Metals Limited shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and 29Metals Limited wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 20 Feb 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

  • Why are ASX 200 gold stocks like Northern Star and Newmont down so much today?

    a person holds their head in their hands as they slump forward over a laptop computer which features a thick red downward arrow zigzagging downwards across the screen.

    S&P/ASX 200 Index (ASX: XJO) gold stocks, including Northern Star Resources Ltd (ASX: NST) and Newmont Corp (ASX: NEM), are getting smashed on Thursday.

    In morning trade, the ASX 200 is down 1.6%.

    But the gold miners are doing it much tougher today as witnessed by the 7.1% decline in the S&P/ASX All Ordinaries Gold Index (ASX: XGD).

    Here’s how some of the top ASX 200 gold stock are performing at this same time:

    • Northern Star shares are down 7.0% at $19.48
    • Newmont shares are down 4.9% at $147.69
    • Evolution Mining Ltd (ASX: EVN) shares are down 7.0% at $12.56
    • Ramelius Resources Ltd(ASX: RMS) shares are down 8.7% at $3.69
    • Bellevue Gold Ltd (ASX: BGL) shares are down 9.4% at $1.46
    • Genesis Minerals Ltd (ASX: GMD) shares are down 9.1% at $5.61
    • Perseus Mining Ltd (ASX: PRU) shares are down 6.6% at $4.84
    • Vault Minerals Ltd (ASX: VAU) shares are down 8.6% at $4.23
    • Westgold Resources Ltd (ASX: WGX) shares are down 7.8% at $5.69
    • Ora Banda Mining Ltd (ASX: OBM) shares are down 9.4% at $1.35

    Ouch!

    Here’s what’s got investors reaching for their sell buttons.

    ASX 200 gold stocks in the crosshairs

    After enjoying a tremendous run through to the beginning of March this year, ASX 200 gold stocks like Northern Star and Newmont have come under selling pressure amid a sizeable retrace in the record setting gold price.

    On 2 March, gold was trading for US$5,322 per ounce. Today, that same ounce is trading for US$4,834, according to data from Bloomberg. That sees the gold price down more than 9% this month.

    This comes as the oil price heads the other direction. Brent crude oil is trading or US$107 per barrel today, up 38% since 2 March.

    And it matters for two reasons.

    First, this divergence in the two commodity prices is driving a rotation from ASX 200 gold stocks into ASX 200 energy stocks.

    Woodside Energy Group Ltd (ASX: WDS) shares, for example, are up 4.5% today, while rival Santos Ltd (ASX: STO) shares are up 2.8%.

    The other reason the gold price – and gold miners like Newmont, Northern Star and Evolution Mining – are taking a steep hit is that fast rising energy prices look likely to fuel inflation.

    The Middle East conflict and its impact on global oil prices was cited by Fed officials yesterday when the US central bank opted to keep interest rates on hold. On Tuesday, the RBA also mentioned rising energy costs after it opted to increase interest rates in Australia.

    And gold, which pays no yield itself and is priced in US dollars, tends to do better in a low or falling rate environment.

    The bigger picture

    Longer-term investors in most ASX 200 gold stocks should still be sitting on outsized gains.

    Despite today’s big retrace, the ASX All Ords Gold Index remains up 55.4% over 12 months.

    The post Why are ASX 200 gold stocks like Northern Star and Newmont down so much today? appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Bellevue Gold Limited right now?

    Before you buy Bellevue Gold Limited shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Bellevue Gold Limited wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 20 Feb 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • 3 reasons to buy Telstra shares today

    Five young people sit in a row having fun and interacting with their mobile phones.

    Telstra Group Ltd (ASX: TLS) shares are 0.1% higher in early morning trade on Thursday. At the time of writing, the shares are changing hands at a 10-year high of $5.28 a piece.

    The telco’s stock has leapt higher since it posted its impressive half-year FY26 results last month. Telstra shares are now 8% higher for the year-to-date and an impressive 28% higher than this time last year.

    For context, the S&P/ASX 200 Index (ASX: XJO) has climbed just over 8% over the same 12 month period.

    The past month has been a great success story for Telstra, and I still think the telco is a buy.

    Here are three reasons why to add Telstra shares to your portfolio today.

    1. Telstra is a textbook defensive stock

    Internet access and mobile phone connectivity are necessary for everyday life. This means the company is likely to perform steadily, regardless of what stage of the economic cycle we’re in. 

    Telstra confirmed this recently when it posted a strong half-year FY26 result last month. The company’s profit and earnings increased, and there were gains seen across every financial metric and division.

    The results show that the company has a predictable cash flow and reliable earnings, which is classic for a strong defensive stock. 

    And this is great news for investors who want to hedge against potential volatility elsewhere in the index.

    2. Telstra offers great passive income

    It’s this defensive nature which means Telstra can offer its investors a reliable passive income with a good dividend yield.

    In fact, one of the best things about Telstra is that its dividend payout ratio is close to 100% of its earnings. That unlocks a good dividend yield.

    Telstra pays investors two dividends every year, in March and September. Investors are due to receive an interim 10.5 cent dividend, 90.48% franked, next week. 

    In FY25 the company paid investors an annual dividend of 19 cents per share, which translates to a 3.9% dividend yield at the time of writing. The telco is expected to pay an even larger 20-cent final dividend for FY26, which represents a 5.25% increase year-on-year. For FY27 the dividend payout is expected to increase again to 21 cents per share. 

    3. Analysts are still tipping an upside

    Even after the latest price rally, some analysts are still tipping more upside ahead for Telstra shares.

    TradingView data shows that five out of 15 analysts have a buy or strong buy rating on Telstra shares. The other 10 have a hold rating.

    The maximum target price is $5.60, which implies a potential 6% upside at the time of writing.

    The post 3 reasons to buy Telstra shares today appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Telstra Corporation Limited right now?

    Before you buy Telstra Corporation Limited shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telstra Corporation Limited wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 20 Feb 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Down 87% since Friday, why is this ASX 300 healthcare stock sliding again today?

    Scientists in white coats look disappointed as the Starpharma share price falls today

    S&P/ASX 300 Index (ASX: XKO) healthcare stock Immutep Ltd (ASX: IMM) has been on a decidedly wild ride these past four trading days.

    After entering a trading halt on Monday, 9 March, Immutep shares resumed trading last Friday. And by the time the closing bell sounded, the Immutep share price had crashed a very painful 88.6%.

    Investors were overheating their sell buttons on the day, after the ASX 300 healthcare stock reported that the Phase III lung cancer study of its eftilagimod alfa (efti) product had been discontinued.

    “We are very disappointed and surprised with the outcome of the futility analysis, in light of efti’s performance in every other clinical trial,” Immutep CEO Marc Voigt said at the time.

    On Monday, bargain hunters swooped in, sending the Immutep share price up 35.6% by close. But a lot of those gains evaporated again on Tuesday, with shares closing the day down a sharp 16.4%.

    See what I mean about a ‘decidedly wild ride’?

    Now, here’s what’s happening today.

    ASX 300 healthcare stock slides again

    The Immutep share price is slumping again today, down 1.9% in morning trade at 5.1 cents. That sees the share price down 87.3% since exiting its trading halt on Friday, as investors appear to have lost confidence in the company’s outlook.

    Today’s fall comes despite the company announcing positive results this morning from the first-in-human Phase I study in healthy participants evaluating IMP761.

    According to the release, IMP761 is a first-in-class LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signalling, potentially suppressing pathogenic T cell responses in autoimmune diseases.

    (Quite a mouthful, I know!)

    The ASX 300 healthcare stock reported that the single ascending dose portion of the study has been successfully completed. The drug was well tolerated across all dose levels, with no safety concerns or dose-limiting toxicities observed.

    The study is now progressing in the multiple ascending dose portion, which is evaluating pharmacokinetics and safety across two dose levels. Immutep expects to complete this stage of the study in the third quarter of calendar year 2026.

    What did management say?

    Commenting on the new trial results that have yet to lift the ASX 300 healthcare stock today, Immutep chief scientific officer Frederic Triebel said:

    IMP761 continues to show a clear immunosuppressive effect in healthy participants challenged with a foreign antigen in an intra-dermal reaction, with durable inhibition of T-cell–mediated responses after a single administration.

    These first-in-human findings support our mechanistic aim of selectively silencing pathogenic, self-antigen–specific memory T cells via LAG–3 agonism and provide the basis for dose levels to be tested in a future phase II trial in patients with autoimmunity.

    Immutep said it will present the results of the phase I trial at the European Alliance of Associations for Rheumatology annual congress in London on 4 June.

    The post Down 87% since Friday, why is this ASX 300 healthcare stock sliding again today? appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Immutep Limited right now?

    Before you buy Immutep Limited shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Immutep Limited wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 20 Feb 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Charter Hall Long WALE REIT declares March 2026 distribution and DRP update

    Australian dollar notes in the pocket of a man's jeans, symbolising dividends.

    Charter Hall Long WALE REIT (ASX: CLW) has announced a quarterly distribution of 6.375 cents per unit, unfranked, to be paid on 15 May 2026. The distribution relates to the quarter ending 31 March 2026.

    What did Charter Hall Long WALE REIT report?

    • Quarterly distribution of 6.375 cents per unit, unfranked
    • Ex-dividend date: 30 March 2026
    • Record date: 31 March 2026
    • Payment date: 15 May 2026
    • Distribution Reinvestment Plan (DRP) available with a 1% discount

    What else do investors need to know?

    The DRP allows investors to reinvest their distributions at a 1% discount to the average daily volume weighted average price between 7 and 20 April 2026. The last date to elect participation in the DRP is 1 April 2026. DRP pricing details will be confirmed in a separate announcement on or around 15 May 2026.

    The distribution is fully unfranked and not designated as conduit foreign income. Investors who do not elect to participate in the DRP will receive their distribution as a standard cash payment.

    What’s next for Charter Hall Long WALE REIT?

    Charter Hall Long WALE REIT continues to provide regular income to its unit holders through quarterly distributions. Investors may review their DRP options ahead of the April 1 deadline, while details of the DRP price will be provided closer to the payment date.

    The REIT remains focused on maintaining a strong and predictable income stream for investors, underpinned by a diversified portfolio of properties with long lease terms.

    Charter Hall Long WALE REIT share price snapshot

    Over the past 12 months, Charter Hall Long WALE REIT shares have declined 6%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

    View Original Announcement

    The post Charter Hall Long WALE REIT declares March 2026 distribution and DRP update appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Charter Hall Long WALE REIT right now?

    Before you buy Charter Hall Long WALE REIT shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Charter Hall Long WALE REIT wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 20 Feb 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

  • Which ASX biotech’s shares have jumped more than 10% on positive clinical trial news?

    Female scientist working in a laboratory.

    Shares in Racura Oncology Ltd (ASX: RAC) have jumped more than 10% in early trade after the company announced the successful first dosing of a patient in Hong Kong with its RC220 cancer compound.

    The company said in a statement to the ASX that the patient was the third to be dosed with the compound, but the first at the Hong Kong Site.

    Good early signs

    Racura said no vein inflammation or other adverse events were reported following the dosing, and to date, no dose-limiting toxicities have been observed in any of the three patients dosed.

    The company added:

    Dosing of the third patient also completes recruitment of the first trial cohort. In accordance with the trial protocol, the Safety Review Committee (SRC) will review all accumulated safety data collected from the three patients. Subject to SRC review and clearance, the trial will then progress to the next planned RC220 dose level of 80 mg/m2 using the updated trial protocol announced 11 February 2026.

    Racura Chief Executive Officer Dr Daniel Tillett said on Thursday:

    The safe dosing of the third patient in our RC220 solid tumour trial in Hong Kong and recruitment of the first dose escalation cohort is an important milestone for Racura Oncology. We are grateful to all the patients, investigators, and clinical teams who have made this trial possible and we look forward to treating patients on the updated protocol.

    Stage 1 of the RC220 trial will be carried out across Australia, Hong Kong, and South Korea, and involves ascending doses “to determine the safety, tolerability, pharmacokinetics, and maximum tolerated combined dose of RC220 in combination with doxorubicin in up to 33 patients”.

    After interim analysis of the data, another 20 patients will be administered the compound to test for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals, Racura said.

    Multiple uses being examined

    Racura said in its statement to the ASX that RC220 was being tested to address the high unmet needs of patients across multiple cancer indications with a Phase 3 clinical program in acute myeloid leukemia, a Phase 1a/b program in lung cancer, and the trial mentioned previously, which aims to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

    The ASX biotech’s shares traded as high as $2.73 on the news, up 14.7%, before settling back to be 8.8% higher at $2.57.

    Racura was valued at $433 million at the close of trade on Wednesday.

    The post Which ASX biotech’s shares have jumped more than 10% on positive clinical trial news? appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Racura Oncology right now?

    Before you buy Racura Oncology shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Racura Oncology wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 20 Feb 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • If a 30-year-old invests $500 a month in ASX stocks, here’s what they could have by retirement

    A trendy woman wearing sunglasses splashes cash notes from her hands.

    ASX stocks could be the ticket for younger investors to become a lot wealthier over time. Investing just $500 per month can compound into a very pleasing figure by retirement.

    It’s easy to underestimate how powerful compounding can be. One of the world’s greatest ever minds, Albert Einstein, once supposedly said:

    Compound interest is the most powerful force in the universe. Compound interest is the eighth wonder of the world. He who understands it, earns it; he who doesn’t pays it.

    Someone who is 30 now may have 40 years to grow their nest egg until retirement age. People can retire earlier than 70 if they’re able and willing to.

    How much could someone’s wealth actually grow? Let’s take a look.

    The long-term goal

    Growing wealth towards retirement can take a while, but it’s very rewarding to see it grow over time. Planting a sapling (in the right place) will become a sizeable tree – but we need to be patient.

    I think it’s a great move to regularly invest in ASX stocks. The ASX share market has returned an average of 10% per year over the ultra-long-term. That level of return is very satisfactory.

    For example, if $5,000 were invested today and it grew by an average of 10% per year for 40 years, it’d become $226,296.

    It’s hard to say what a good figure will be for retirement in 40 years from now, but it’ll probably need to be more than $226,000.

    In the current inflationary environment, it could be harder to save $500 per month. However a household does it, to invest we need to spend less than we earn to unlock those monthly savings.

    If someone invested $500 per month and it grew by 10% per year for 40 years, it’d become $2.65 million. That’d be a really nice level of wealth, in my eyes. Remember, it assumes investing $500 throughout the process. Being able to invest more during some later years will help it become much larger.

    How can someone accelerate reaching retirement?

    I’d understand wanting to retire earlier than 70, and there are two main ways to do so.

    Firstly, someone can invest more each month, though that’s easier said than done.

    Second, we can choose investments that deliver higher returns. For example, if an investment returned 12% per year, then investing $500 per month would grow to around $2.6 million in 35 years – seeing stronger returns could shave 5 years off retirement age.

    I’d look at ASX growth stocks and international shares as ideas that could outperform the wider ASX share market. One exchange-traded fund (ETF) to consider is Vanguard MSCI Index International Shares ETF (ASX: VGS). There are plenty of great ASX growth stocks at good prices right now.

    The post If a 30-year-old invests $500 a month in ASX stocks, here’s what they could have by retirement appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Vanguard MSCI Index International Shares ETF right now?

    Before you buy Vanguard MSCI Index International Shares ETF shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Vanguard MSCI Index International Shares ETF wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 20 Feb 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Vanguard Msci Index International Shares ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • 2 great ASX 200 blue-chip shares I’d buy right now

    A person holds strong behind their umbrella as they weather the oncoming storm.

    There is a lot of market volatility right now, giving investors plenty to think about. I think it would be a good call to invest in S&P/ASX 200 Index (ASX: XJO) blue-chip shares that can deliver solid profit growth and outperform the market.

    I’m still optimistic about what the long-term holds for Australia and the ASX share market as a whole. But the short-term can throw up some issues.

    If I were looking for which ASX 200 blue-chip shares to buy, the following names could be some of the best ones to own over the next year and the rest of the decade.

    Coles Group Ltd (ASX: COL)

    Coles is the second-largest supermarket business in Australia, and it continues to grow in size through both total sales and its supermarket network.

    The ASX 200 blue-chip share delivered an impressive first-half FY26 report, with total revenue growth of 3.6% and underlying net profit growth of 12.5%.

    Sales growth remained pleasing in the first seven weeks of the second half of FY26, with supermarket revenue up 3.7% (5.3% excluding tobacco).

    Coles has attracted customers with its wider range of own-brand products and exclusive Coles items, while also offering convenience and improved value.

    I don’t know how this new period of inflation will play out, but if it leads to higher food prices, then Coles may be able to pass on price rises again. But, there’ll probably be widespread attention on its gross profit margin.

    However, its growing scale and new, advanced warehouses should help the company improve its bottom line in the coming years.

    Based on CommSec’s forecasts, the ASX 200 blue-chip share is trading at 23x FY26’s estimated earnings, with a grossed-up dividend yield of 5.2% including franking credits.

    Wesfarmers Ltd (ASX: WES)

    Wesfarmers owns a number of leading Australian businesses, including Bunnings, Kmart, Officeworks, and Priceline. Other parts of its business include Target, InstantScripts, WesCEF (chemicals, energy and fertilisers), an industrial and safety division, and more.

    I like the diversification that Wesfarmers has – it’s not too exposed to one area and has the ability to invest in whatever area of its current business (or a new business) it needs to generate the best profit growth for shareholders.

    Kmart and Bunnings have continued to deliver sales growth in both HY26 and at the start of the second half of FY26, which I think is an important driver of future value for investors. Wesfarmers’ two main businesses offer customers great value products, which could help them perform and gain market share during this period of potential higher inflation.

    Wesfarmers’ rising profit margins and high return on equity (ROE) make sales growth very rewarding for the business.

    The ASX 200 blue-chip share continues to expand its growth avenues, such as selling Anko products in the Philippines, which could become increasingly useful to the overall Wesfarmers picture.

    According to the CommSec forecast, the Wesfarmers share price is valued at under 30x FY26’s estimated earnings, with a grossed-up dividend yield of 4.1% including franking credits.

    The post 2 great ASX 200 blue-chip shares I’d buy right now appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Wesfarmers Limited right now?

    Before you buy Wesfarmers Limited shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Wesfarmers Limited wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 20 Feb 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Wesfarmers. The Motley Fool Australia has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.